Back to Directory
Dapiglutide
Metabolic & Weight ManagementUltra-long-acting GLP-1 agonist for monthly dosing being developed for diabetes and obesity.
Key Benefits
- ✓Once-monthly dosing
- ✓Weight loss
- ✓Glucose control
- ✓Maximum convenience
- ✓Long-acting GLP-1 effects
Dosing Information
Dosage Range
Under investigation
Frequency
Once monthly
Typical Duration
Under development
Detailed Protocol
Under development. Designed for subcutaneous injection once monthly. Phase 1/2 trials.
About Dapiglutide
Dapiglutide is a novel long-acting GLP-1 receptor agonist designed for once-monthly administration. Being developed by Eli Lilly for type 2 diabetes and obesity. Extended half-life through fatty acid modification.
Research Notes
Early-stage development for monthly GLP-1 therapy. Represents ultimate convenience in this class. Phase 1 data presented showing feasibility of monthly dosing.
Potential Side Effects
- •Expected GLP-1 side effects
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.